Evaluation of Circulatory RNA-Based Biomarker Panel in Hepatocellular Carcinoma

El-Tawdi, Ahmed Hassan Fawzi; Matboli, Marwa; Shehata, Hanan H.; Tash, Fathy; El-Khazragy⃰, Nashwa; Azazy, Ahmed E M; Abdel‐Rahman, Omar

doi:10.1007/s40291-016-0200-9

Cited by 38 publications

(32 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1, 287 articles from databases were initially identified; titles and abstracts were reviewed after 98 duplicated articles were excluded; due to letters, reviews, meta-analyses, or irrelevant research topic, further 166 articles were excluded, leaving 23 articles for full-text review; as a result, 13 articles were finally excluded due to unrelated to cancer diagnosis, insufficient data, or irrelevant to our topic. Finally, 10 articles [27–36] containing 19 studies were identified.…”

Section: Resultsmentioning

confidence: 99%

Diagnostic value of long noncoding RNAs for hepatocellular carcinoma

et al. 2017

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Diagnostic value of long noncoding RNAs for hepatocellular carcinoma

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Long Non-Coding RNA MALAT1 Regulates ZEB1 Expression by Sponging miR-143-3p and Promotes Hepatocellular Carcinoma Progression [28]. The lncRNA-CTBP has also been identified had high sensitivity and specificity for discriminating HCC from healthy controls and also from CH patients [29]. Tang et al also published the results that lncRNAs might act as biomarker for the diagnosis of HCC from healthy control and CH patients [30].…”

Section: Discussionmentioning

confidence: 99%

Circulating LncRNAs Serve as Diagnostic Markers for Hepatocellular Carcinoma

Yuan¹,

Sun²,

Liu³

et al. 2017

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Circulating (serous or plasmic) long non-coding RNA (lncRNA) as biomarkers for predicting the diagnosis or prognosis of human disease have been well documented. Due to the sensibility or specificity limitation of Alpha Fetoprotein (AFP), a cluster lncRNAs were revealed as fingerprints for hepatocellular carcinoma (HCC). In this study, we enrolled all the reported circulating lncRNAs in HCC as candidate targets and examined in an independent cohort. Methods: The candidate lncRNAs were determined by qRT-PCR divided into training and validation sets. The risk score analysis was employed to evaluate the potential diagnosis ability of the lncRNAs independently or combining with AFP value. The receiver operating characteristic curve (ROC) was applied for presentation of sensibility or specificity. Results: Among the ten candidate circulating lncRNA, LINC00152, RP11-160H22.5, XLOC014172 and LOC149086 were screened with significant difference in training set. Further investigation in validation set indicated LINC00152, RP11-160H22.5 and XLOC014172 might be the fingerprints for HCC comparing with chronic hepatitis (CH) patients or healthy controls. The risk score analysis revealed the combination of three lncRNAs with AFP could distinguish the HCC from either CH or healthy control with the area under curve value (AUC) of 0.986 and 0.985, respectively. Conclusion: The three lncRNAs may act as novel biomarkers for acting as fingerprint in HCC combining with AFP.

show abstract

“…The combination of lncRNA and miRNAs has been also studied. lncRNA-CTBP, miR-16-2, miR-21-5p and LAMP2 had high sensitivities (91%, 92.3%, 93.6% and 92.3% respectively) for discriminating HCC from healthy subjects and also from chronic hepatitis C patients (75%, 88.9%, 88.9% and 94.9% respectively) [123] . miR-224 was highly expressed in HCC tissue and plasma, and after surgery the levels were normalized suggesting that miR-224 could reflect tumor dynamisms.…”

Section: Circulating Mirnasmentioning

confidence: 98%

Performance of different biomarkers for the management of hepatocellular carcinoma

Rojas¹,

Sánchez‐Torrijos²,

Gil‐Gómez³

et al. 2018

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the second cause of cancer related death due to latent liver disease, late diagnosis and non-available therapeutic treatment. Liver biopsy is still the gold standard in order to know the molecular biology of the tumor, its behaviour and invasive characteristics. Conventional diagnosis methods for HCC detection include imaging and serological tests with low sensitivity and specificity. In this review, we focus on the potential utility of certain serum biomarkers and a new approach, "liquid biopsy", in the management of HCC patients.

show abstract

Evaluation of Circulatory RNA-Based Biomarker Panel in Hepatocellular Carcinoma

Abstract: The circulatory RNA-based biomarker panel can serve as a potential biomarker for HCC diagnosis and prognosis.

Cited by 38 publications

References 49 publications

Diagnostic value of long noncoding RNAs for hepatocellular carcinoma

Diagnostic value of long noncoding RNAs for hepatocellular carcinoma

Circulating LncRNAs Serve as Diagnostic Markers for Hepatocellular Carcinoma

Performance of different biomarkers for the management of hepatocellular carcinoma

Contact Info

Product

Resources

About